Ignite Creation Date:
2025-12-24 @ 1:57 PM
Ignite Modification Date:
2026-01-29 @ 1:25 PM
Study NCT ID:
NCT05911295
Status:
RECRUITING
Last Update Posted:
2025-12-15
First Post:
2023-06-09
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
Sponsor:
Seagen, a wholly owned subsidiary of Pfizer
Organization:
Conditions & Keywords Data
Conditions:
Conditions
| Condition Brief | Condition Text | View |
|---|---|---|
| None | Urothelial Carcinoma | View |